Mayflower Financial Advisors’s Elicio Therapeutics ELTX Stock Holding History

Mayflower Financial Advisors’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.1K	Hold	10,000	–	–	﹤0.01%	495
2026 Q1	$107K	Hold	10,000	–	–	0.01%	436
2025 Q4	$79.6K	Hold	10,000	–	–	0.01%	411
2025 Q3	$109K	Hold	10,000	–	–	0.01%	404
2025 Q2	$77.2K	Buy	+10,000	New	+$62.2K	0.01%	389

Other funds holding ELTX

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

MLL

Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Mayflower Financial Advisors's ELTX Position: Q2 2026 in Review

Mayflower Financial Advisors held its Elicio Therapeutics (ELTX) position steady in Q2 2026 at 10,000 shares worth $39.1K. The position accounts for ﹤0.01% of the portfolio, ranked #495.

Mayflower Financial Advisors first reported a position in ELTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $109K in Q3 2025. 5 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Mayflower Financial Advisors held 10,000 shares of Elicio Therapeutics worth $39.1K as of Q2 2026.
Mayflower Financial Advisors left its Elicio Therapeutics share count unchanged in Q2 2026.
Elicio Therapeutics made up ﹤0.01% of Mayflower Financial Advisors's portfolio in Q2 2026, its #495 holding.
Mayflower Financial Advisors first reported a position in Elicio Therapeutics in Q2 2025 and has held it in 5 quarters since.
Mayflower Financial Advisors's Elicio Therapeutics position peaked at $109K in Q3 2025.
5 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Mayflower Financial Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.